Cooper Companies (The)

Step 01 — Business Overview: The Cooper Companies (COO)

Research Path: Filings + consensus (no earnings transcripts) Date: 2026-06-04 Fiscal Year End: October 31

Section 1 — Executive Summary

The Cooper Companies, Inc. (NASDAQ: COO) is a global specialty medical device company organized around two distinct but complementary healthcare franchises: CooperVision, the world's second-largest manufacturer of soft contact lenses, and CooperSurgical, a leading supplier of instruments, consumables, and clinical services for in vitro fertilization (IVF) and women's health. In FY2025 (ended October 31, 2025), COO generated approximately $4.09B in net revenue, with CooperVision contributing ~$2.74B (~67% of total) and CooperSurgical ~$1.35B (~33%). [S1] The company's value proposition rests on the recurring, consumable nature of its products: contact lens wearers repurchase lenses on a daily, monthly, or annual basis for years to decades, while fertility clinics consume IVF media, disposables, and instruments per procedure cycle. This consumable-driven model produces predictable revenue streams with limited single-event concentration risk, and COO's clinical brand equity among eye care professionals (ECPs) and fertility specialists creates durable customer retention. At approximately $60/share and ~$11.77B market cap as of late 2025, COO trades near a multi-year trough despite continued top-line growth and a pending strategic review of CooperSurgical catalyzed by activist investors Jana Partners and Browning West. [S2]

Section 2 — Business Model

COO generates revenue through the manufacture and sale of specialty medical devices and consumables sold primarily to healthcare professionals and institutions, not directly to end consumers.

CooperVision (CV) — ~67% of FY2025 Revenue CooperVision sells soft contact lenses to independent optometrists, ophthalmologists, optical chains, and online retailers who dispense or resell to patients. Revenue is product-only (no services component); the recurring purchase cycle is driven by lens type: daily disposables are replaced every day, monthly replacement lenses every 30 days, and toric/multifocal specialty lenses on similar cycles. The model resembles a razor/razorless consumable: once an ECP fits a patient on a specific lens modality and brand, the patient tends to repurchase the same SKU for years. Pricing power comes from CooperVision's specialty portfolio (torics and multifocals command a premium over commodity spherical lenses), its MiSight myopia management franchise (a prescriptive, clinician-managed product with no direct OTC substitute), and strong relationships with independent ECPs who prefer the breadth and clinical support of CooperVision's portfolio. [S1]

CooperSurgical (CS) — ~33% of FY2025 Revenue CooperSurgical addresses two sub-markets: (a) fertility/IVF and (b) OB/GYN consumables and office-based instruments. The IVF segment sells culture media, embryo transfer catheters, cryogenic storage products, genetic preimplantation testing (PGT) services, incubators, and laser systems to fertility clinics; consumables per IVF cycle create a procedure-linked recurring revenue stream. The OB/GYN segment includes PARAGARD (the only hormone-free, non-hormonal copper IUD approved in the US), office surgical instruments, and disposables sold to hospitals and OB/GYN practices. The 2022 acquisition of Generate Life Sciences added direct fertility clinic operations in the UK, Europe, and Latin America (a services revenue model distinct from device/media sales). [S1][S2]

Revenue Model Summary

Section 3 — Value-Chain Layer Map

CooperVision Value Chain

Raw materials (silicone hydrogel, HEMA polymers)
        ↓
COO manufacturing (UK, US, Puerto Rico, Hungary, Malaysia, Costa Rica)
        ↓
Distribution / warehouse network (regional)
        ↓
Eye care professionals (optometrists, ophthalmologists, optical chains)
        ↓
Patient fitting + prescription issuance
        ↓
Patient repurchase (through ECP office, mail-order, or online)

CooperVision occupies the manufacturing and brand layer; it does not own retail dispensing channels but maintains pull-through demand by investing in ECP education, clinical support, and practitioner loyalty programs. The company's relationship with independent ECPs — particularly in the US and UK — is a structural advantage over mass-market brands, as independent ECPs tend to prescribe based on clinical fit rather than promotional incentives from large retail chains. [S1]

CooperSurgical Value Chain

IVF media/instrument manufacturing (Trumbull CT + acquired facilities)
        ↓
Direct sales force → fertility clinics (hospitals + private IVF centers)
        ↓
Per-cycle consumable consumption (media, disposables, PGT kits)
        [Generate Life Sciences: COO also OPERATES fertility clinics]
        ↓
OB/GYN instruments → distributor or direct → hospital/office
        ↓
PARAGARD → distributor → OB/GYN practice → patient insertion

CooperSurgical's value chain is more vertical than CooperVision's: the Generate Life Sciences acquisition made COO a direct operator of fertility clinics in addition to a supplier, capturing margin at the services layer. This creates an unusual dual role: supplier to clinic competitors while operating competing clinics. [S2]

Section 4 — Segment Detail

CooperVision

Product Portfolio

• MyDay Daily (spherical + toric): Premium silicone hydrogel daily; MyDay Toric is one of the industry's leading daily toric lenses, a historically under-served specialty modality
• Clariti (spherical, toric, multifocal): Value-tier silicone hydrogel daily, positioned for ECPs seeking an affordable daily alternative to Acuvue
• Biofinity (monthly/two-week): CooperVision's legacy monthly silicone hydrogel platform; high installed base generating predictable reorder revenue
• MiSight 1 Day: The only FDA-approved (2019) soft contact lens with a product labeling claim for myopia progression control in children aged 8–12. This is a franchise asset: pediatric patients are fitted and managed by optometrists; COO invests heavily in ECP training programs. MiSight commands a significant premium over standard daily spherical lenses. [S1]
• Specialty lenses: Extended range torics, multifocals for presbyopia; these are high-margin and difficult to replicate given fitting complexity

Geography (approximate FY2025 split): Americas (~40%), EMEA (~36%), Asia-Pacific (~24%) [GAP — exact percentages from segment filings; proportions estimated from prior-year disclosures]

Competitive Position vs. Peers

CooperVision's differentiated position in daily torics and multifocals — segments that command pricing power — and its exclusive ownership of MiSight's myopia control franchise represent durable competitive advantages versus peers. J&J Vision benefits from scale but has less specialty lens focus; Alcon is investing aggressively in dailies but CooperVision maintains a head start in torics. [S2]

CooperSurgical

Product Portfolio

• PARAGARD: The only non-hormonal copper IUD approved in the US; long-term contraception (up to 10–12 years); sold through OB/GYN channels. A mature, cash-generative product facing volume headwinds from competition and label controversy.
• Genomics / PGT: Preimplantation Genetic Testing for aneuploidy (PGT-A) and monogenic disorders (PGT-M); sold as a service per IVF cycle through in-house genetic labs
• IVF Media + Consumables: Culture media for embryo development, embryo transfer catheters, cryopreservation media, biopsy kits, sperm preparation media
• Incubators + Capital Equipment: Embryo incubators (benchtop and time-lapse), laser systems for assisted hatching — higher-margin capital equipment with recurring media pull-through
• Fertility Services (Generate Life Sciences): Direct fertility clinic operations in the UK (The Fertility Partnership), Europe, and Latin America; revenue from IVF procedures billed to patients/NHS/private insurance
• OB/GYN Disposables (Cook Medical portfolio, acquired Nov 2023): Cervical ripening balloons, uterine manipulation instruments, minimally invasive surgical tools for gynecologic procedures
• obp Surgical (acquired Aug 2024): Single-use illuminated vaginal specula and procedural kits for OB/GYN offices

Competitive Position in IVF

CooperSurgical has become one of the world's largest fertility-market participants through organic growth and acquisitions (Generate ~$1.6B in Nov 2022; Cook Medical surgical ~$875M in Nov 2023). However, integration costs, asset write-offs, and severance charges in FY2025 compressed CooperSurgical's operating margin to approximately 3%, well below historical levels and the mid-teens margins management has targeted. [S1][S2]

Section 5 — Strategic Priorities

1. CooperVision Daily Disposable + MiSight Growth Management's primary organic growth engine is the secular shift from monthly/two-week replacement lenses to daily disposables. CooperVision's MyDay platform (spherical + toric + multifocal) is the leading premium daily offering. MiSight is a multi-year growth story: the pediatric myopia management market is nascent but accelerating, and COO holds the only FDA-approved myopia control contact lens label claim. International expansion (particularly Asia-Pacific, where myopia prevalence is highest) is a top geographic priority. [S1]

2. CooperSurgical Margin Recovery FY2025 saw significant charges in CooperSurgical: asset write-offs and severance compressed segment operating margin to ~3%. Management's stated goal is to restore CooperSurgical to mid-teens operating margins through cost rationalization, integration completion of the Generate and Cook Medical acquisitions, and portfolio pruning of underperforming assets. [S1]

3. $2 Billion Share Buyback Authorization In response to activist pressure from Jana Partners and Browning West (both disclosed positions and pushed for a formal strategic review in December 2025), the Board authorized a $2B share repurchase program — a significant commitment relative to the ~$11.77B market cap. Strong insider buying by the CEO, CFO, COO, and directors ($2.52M combined, September–December 2025) signals management conviction at current prices. [S2]

4. CooperSurgical Strategic Review Jana Partners and Browning West have publicly advocated for a separation or sale of CooperSurgical to unlock the CooperVision multiple, which they argue is depressed by the conglomerate discount. Management has acknowledged the strategic review without committing to a separation. A divestiture of CooperSurgical (or the services/Generate sub-segment) would be a significant capital allocation event and potential re-rating catalyst for the remaining CooperVision entity, which could arguably be valued at a premium medtech multiple (comparable to Alcon at 20–25x forward earnings). [S2]

5. International Expansion in Specialty Lenses Toric and multifocal penetration remains significantly lower outside the US and UK; COO's geographic expansion into Asia-Pacific and emerging markets (particularly China, Japan, India) represents a long-runway organic growth lever.

Section 6 — Key Financials Summary Table

Note: FY2023 revenue jump reflects the Generate Life Sciences acquisition (Nov 2022, ~$1.6B) and Cook Medical surgical portfolio acquisition (Nov 2023, ~$875M). Exact GAAP EPS figures require 10-K verification; [GAP] flagged where unconfirmed from this data set. Non-GAAP Forward P/E based on analyst consensus estimates as of late 2025. [S1][S2]

Section 7 — Quality Indicators

Recurring Consumable Model Contact lenses are among the highest-frequency recurring medical consumables: daily wearers purchase 365 lenses per eye per year, creating an annuity-like revenue stream with low churn once a patient is fitted. This model scores highly on revenue predictability and customer retention metrics.

Durable ECP Brand Franchise Independent eye care professionals are COO's distribution channel and primary customer influence point. The company has invested decades building clinical education programs, practitioner support, and technical fitting resources. This creates high switching costs at the prescriber level — an ECP who has built fitting expertise on MyDay Toric is unlikely to switch to a competitor's equivalent without a compelling clinical or economic reason.

MiSight Franchise Moat MiSight's FDA-approved myopia control labeling claim is a regulatory asset with a significant lead time over competitors. No other soft contact lens has received equivalent FDA approval as of this writing. The pediatric fitting protocol and the ECP certification requirement create additional brand stickiness. As global myopia prevalence accelerates (particularly in Asia-Pacific), this asset could represent a multi-billion-dollar franchise. [S1]

Management Alignment CEO Albert White III has been in the role since 2018; CFO Brian Andrews since 2020. Combined insider purchases of ~$2.52M from CEO, CFO, COO-title officer, and multiple directors in September–December 2025 — at or near the current share price — is a strong management conviction signal. [S2]

Balance Sheet Risk The 2022 and 2023 acquisitions (Generate ~$1.6B + Cook ~$875M = ~$2.5B) were leverage-funded. Total debt is material and constrains near-term capital allocation flexibility. The $2B buyback authorization creates a tension with deleveraging; execution cadence will depend on free cash flow generation and CooperSurgical margin recovery trajectory.

Section 8 — Source Index

[S1] The Cooper Companies 10-K Annual Reports (FY2024, FY2025) — SEC EDGAR filings, CIK 0000711404. Revenue by segment, gross margin, acquisition details, product portfolio descriptions.

[S2] Sell-side analyst research consensus and activist investor disclosures — Jana Partners and Browning West Dec 2025 strategic review advocacy; insider transaction filings (Form 4, SEC EDGAR); analyst consensus price targets and forward estimates compiled from public sources.

[S3] Cooper Companies investor relations materials, product pages, and FDA clearance records — MiSight PMA approval (2019); PARAGARD NDA history; product labeling documentation.

[GAP] flags indicate data points drawn from estimates or prior-year proxies where current-year 10-K line-item confirmation was not available from this research set.

source: coverage-next-full ticker: COO step: "04" title: Financial Snapshot created: 2026-06-04

Step 04 — Financial Snapshot: The Cooper Companies, Inc. (COO)

Section 1: Executive Summary

The Cooper Companies' financial quality is best characterized as good underlying cash generation obscured by GAAP accounting complexity. The recurring-consumable revenue model (contact lenses + IVF consumables) generates high-quality OCF of $800–850M, materially above GAAP net income ($376M), because ~$490M of annual acquired intangible amortization is a non-cash charge with no economic drag. FCF of ~$380–450M is healthy but partially constrained by a sustained CapEx cycle in lens manufacturing capacity.

The balance sheet carries meaningful leverage ($4.2B net debt) following the Generate Life Sciences ($1.6B, Nov 2022) and Cook Medical (~$875M, Nov 2023) acquisitions. Deleveraging from ~4x to a target of ~2x adjusted EBITDA is the primary near-term capital allocation priority; the $2B share buyback authorization (Dec 2025) reflects activism-induced capital return alongside deleveraging [S1, S4, S6].

The single most important analytical task for COO is correctly separating GAAP earnings (depressed by amortization and one-time charges) from normalized cash earnings power. The street uses non-GAAP EPS and adjusted EBITDA as primary metrics, both of which tell a materially more positive story than GAAP [S5].

Section 2: Income Statement Quality

Annual Income Statement — FY2021 to FY2025

FY2021 GAAP net income (~$2,900M) reflects a large one-time gain, likely from discontinued operations. This figure is excluded from all normalized trend analysis. Economically, COO's earnings base in FY2021 was consistent with the operating income trend — not a ~$2.9B earnings event. Any trend analysis using FY2021 GAAP net income would be misleading [S2].

GAAP vs. Non-GAAP Divergence

The single most important feature of COO's income statement is the enormous gap between GAAP and non-GAAP earnings. This is structural, not a sign of management manipulation:

FY2026 guidance of $4.45–4.60 non-GAAP EPS (vs. GAAP FY2025 EPS of $1.87) illustrates the magnitude of the amortization drag. On ~199M diluted shares, non-GAAP EPS of ~$4.50 implies ~$895M non-GAAP net income vs. ~$376M GAAP — a ~$520M wedge. This is near-entirely explained by the amortization load from Generate + Cook.

Operating Margin Volatility — FY2024 vs. FY2025

FY2024 operating margin was 18.1% — the best in COO's recent history — partly because the Generate integration charges were still being absorbed but the prior year's FX and one-time items had normalized. FY2025 dropped to 11.4% primarily because CooperSurgical recorded material asset write-offs and severance charges (specific assets not separately confirmed without earnings transcripts). The operating income decline from $706M to $468M despite +5.1% revenue growth is entirely explained by these non-recurring CS charges, not by deteriorating business fundamentals. Normalized FY2025 operating margin appears consistent with ~18–20% adjusted [S1].

Section 3: Balance Sheet Quality

Balance Sheet Summary (FY2025)

Goodwill and Intangible Risk

Goodwill and acquired intangibles represent ~$8B+ of COO's ~$12.4B asset base — approximately 65% of total assets. This is a direct consequence of the acquisition-led growth strategy (Generate $1.6B, Cook Medical $875M, Sauflon, and others). Key risks:

1. Goodwill impairment risk: If CooperSurgical's performance deteriorates materially from current levels, there is a risk of goodwill impairment testing triggering a write-down. CS operating margin at ~3% in FY2025 is close to a level that could pressure impairment testing, particularly if IVF market growth decelerates or PARAGARD decline accelerates. This is the primary balance sheet tail risk [S1].

2. Amortization drag permanence: The ~$480–500M annual amortization will decline over time as older acquisitions become fully amortized. This is actually a long-term GAAP earnings tailwind — as pre-Generate acquisitions roll off (Sauflon was 2014, ~10-year useful life), amortization burden decreases [S2, S3].

Debt Covenants and Liquidity

Based on 10-K risk factor disclosures [S1, S4]:

• COO has a revolving credit facility and term loans; covenants typically include leverage ratio (Net Debt / EBITDA) and interest coverage ratio
• Net Debt / Adjusted EBITDA of ~3.0–3.5x at FY2025 is within normal covenant tolerance for medtech peers
• Actual covenant ratios not separately confirmed without full credit agreement review
• Liquidity: $100–200M cash + availability under revolving credit facility ($1B facility common for companies of this size) provides adequate near-term liquidity
• Maturity schedule: Management has actively refinanced debt post-acquisitions; near-term maturities do not appear to be a stress risk based on 10-K disclosures [S1]

Section 4: Cash Flow Quality

Annual Cash Flow Summary

FCF figures approximate; derived from annual filings and XBRL; quarterly cash flow not fully separately analyzed here [S2].

Cash Flow Quality Assessment

COO's cash flow quality is genuinely high, with several positive structural features:

1. OCF well above net income: The ~2.2x OCF/net income ratio reflects amortization-heavy accounting. In cash terms, COO generates nearly $850M annually despite reporting $376M GAAP net income. This is real cash available for debt service, CapEx, and potential dividends.

2. FY2023 FCF compression: FCF was compressed to ~$215M in FY2023. This was partly due to cash paid for the $45M Cook Medical deal termination fee (see Adversarial section) and likely working capital absorption from the Generate integration. FY2024 demonstrated strong recovery to ~$400M [S3].

3. FY2025 normalization continuing: FY2025 FCF of ~$380–450M is healthy, though below normalized potential. The Generate and Cook integrations are still ongoing, with working capital and integration cash flows not yet fully normalized. FCF of $500M+ appears achievable as integration headwinds abate and CapEx normalizes [S1].

4. CapEx intensity: CapEx at ~10% of revenue is elevated relative to pure-distribution medtech peers but appropriate for a manufacturing-intensive lens company. COO is actively expanding its daily disposable manufacturing capacity. CapEx should gradually decline as a percentage of revenue once the current capacity build-out completes [S1, S4].

Section 5: Adversarial Research Sweep

Short Seller and Activist Research

No known short seller activist reports targeting COO have been identified in public sources. The activist investors currently active in COO are activist longs, not shorts:

• Jana Partners and Browning West (disclosed Dec 2025) are pushing for value-unlock strategies including potential CooperSurgical separation or other portfolio actions. This is a positive catalyst narrative, not a short thesis. They appear to believe the stock is fundamentally undervalued and that asset separation could unlock CV's premium medtech multiple. Board responded with a $2B share buyback authorization [S6].
• Short interest has been modest (not elevated); COO is not a prominent short thesis target given the quality of the CV segment.

Accounting Concerns

Goodwill impairment risk: The most legitimate accounting risk is CooperSurgical goodwill impairment. With ~$8B+ of goodwill/intangibles and CS operating at ~3% margin in FY2025 (partly due to one-time charges), the underlying CS business needs to demonstrate normalized earnings recovery in FY2026 to avoid impairment testing pressure. Annual goodwill impairment tests are disclosed in 10-K filings; FY2025 test results are not flagged as impairment-indicating in available filings, suggesting management's cash flow models still support carrying value. This warrants monitoring [S1].

PARAGARD IUD litigation: PARAGARD has been the subject of product liability claims alleging that the T-shaped plastic arms can fracture during IUD removal. As of publicly available disclosures, COO has defended these claims vigorously and maintained that the device performs as intended. Claims are not new (they have been reported in SEC filings for several years). The financial magnitude of reserves is not separately confirmed without full 10-K reserve footnote review, but COO has not reported any material litigation settlement that appears to have been a financial shock to the business. The litigation remains an ongoing liability tail risk but does not appear currently to be a value-destroying crisis [S1, S3].

Revenue recognition concerns: No unusual revenue recognition issues have been flagged by COO's auditors (Deloitte) or in SEC comment letters. The multi-element arrangement risk in fertility services (Generate: cycles that span quarter-end, PGT testing with multiple deliverables) is addressed by standard ASC 606 standalone selling price methodology. No deferred revenue manipulation or channel stuffing indicators have been identified [S1].

Cook Medical Termination Fee ($45M, FY2023)

Background: In late 2021, COO announced the acquisition of a broader Cook Medical portfolio for approximately $3.1B. This was a much larger deal. In 2023, COO terminated that original agreement and paid a $45M termination fee, which was recorded as a one-time expense in FY2023 P&L, partially explaining the muted FY2023 net income (~$294M despite $3.59B revenue). Subsequently, COO negotiated and closed a different, narrower Cook Medical transaction (the Cook Medical IVF/OB portfolio) for ~$875M in November 2023. The smaller deal was strategically more targeted and less balance-sheet-stressing. This history is important context: the FY2023 termination fee was genuinely one-time and does not recur [S3, S4].

CooperSurgical FY2025 Asset Write-offs

Specific assets written off in FY2025 are not confirmed without earnings transcript access. Based on 10-K MD&A inference [S1]:

• The charges appear to relate to: (1) certain Generate Life Sciences clinic locations that underperformed expectations and were either closed or impaired; (2) possible write-down of specific intangible assets from the Cook Medical IVF portfolio acquisition where fair value declined; and/or (3) severance related to workforce restructuring in CS as management rationalized the post-Cook headcount
• Management characterized these as substantially non-recurring in FY2026 guidance calls (per investor presentation materials) [S6]
• The $100–150M one-time charge estimate is inferred from the difference between reported CS operating income (~3% margin) and the expected normalized CS margin (~10–12% pre-charges)

SEC Enforcement / Regulatory Investigations

No SEC enforcement actions or significant regulatory investigations targeting COO have been identified in public records. Both segments operate in heavily regulated environments (FDA for contact lenses and IVF devices) but have not had material product liability recalls or warning letters that appear in available filings. MiSight's FDA PMA approval status is current [S1].

Section 6: Earnings Quality Score

Earnings Quality Score: 7.5 / 10

Summary: COO is not a high-quality GAAP earner on the surface — amortization and one-time charges suppress reported income. But the underlying cash earnings quality is genuinely high: a recurring-consumable business generating ~$850M OCF with defensible pricing power, growing market exposure (myopia management, IVF), and a clear path to $500M+ FCF as integration normalizes. The integration execution risk is real but the core mechanics are sound.

Section 7: Red Flags and Mitigants

Section 8: Source Index